AI assistant
Sending…
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023
Feb 14, 2023
30849_dirs_2023-02-14_6c95c74b-29bb-49a4-8552-740320d7c817.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-02-11
Reporting Person: Mazabraud Yann (EVP, Head of International)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-11 | Common Stock | M | 2031 | — | Acquired | 5004 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-11 | Restricted Stock Units | $ | M | 2031 | Disposed | Common Stock (2031) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.
More from RHYTHM PHARMACEUTICALS, INC.
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 3